- Pressemitteilung BoxID 495717
Kuehne + Nagel launches new innovative airfreight solution for pharmaceutical products
KN PharmaChain is Kuehne + Nagel's response to the Pharmaceutical industry's requirements for effective and proper airfreight transportation solutions. If not correctly handled and transported, pharmaceuticals efficacy may be compromised or rendered completely ineffective, resulting in serious and costly consequences, in particular in case of high value, mission critical and temperature sensitive products. Therefore, the choice of a logistics provider is highly important for Pharmaceutical and Health Care companies as they need partners who understand the nature of sensitive products as well as the strict regulatory rules. They must also be familiar with the logistics challenges in both mature and emerging global markets.
Four service levels cater for all needs
KN PharmaChain offers four service levels, depending on the grade of specific temperature control requirements and special handling demands of each shipment. Full risk assessments of carrier partners as well as of transport lanes ensure best-in-class services on all routes within the KN PharmaChain network comprising of 58 strategically designated stations. Comprehensive Best Practice (GxP) policies apply for staff, working processes and facilities, and by the end of 2012, all locations will be fully GxP-compliant.
Kuehne + Nagel plays a pioneering role in shipment visibility
As an option, temperature visibility can be provided by the use of active wireless sensors which record and transmit the shipment temperature throughout the entire transport chain. Logistics facilities are equipped with active wireless transmitting technology and customers can view temperature indications directly inside the KN Login online tracking & tracing tool. Kuehne + Nagel is the first logistics provider to offer a service using active sensors. Additional added-value services include globally available packaging solutions.
Setting new industry benchmarks
Temperature controlled shipments are monitored by the KN PharmaChain CareTeam, operating 24 hours/day and 7 days/week from two locations in Europe and the Americas. An electronic alert system ensures that any disruption in the supply chain will be reported immediately to the CareTeam which is pro-actively tracking all temperature controlled shipments. Industry expertise and product know-how are key elements of KN PharmaChain. This is why Kuehne + Nagel has award-winning training programmes in place which were developed in cooperation with customers.
"KN PharmaChain is our dedicated, end-to-end supply chain solution for Pharma & Healthcare shipments, either temperature or non-temperature controlled. We have developed this product in close cooperation with customers and partners and are convinced that Kuehne + Nagel once again introduces innovative solutions which will set new industry standards", explains Tim Scharwath, Executive Vice President Air Logistics of Kuehne + Nagel International AG.
About Kühne + Nagel International AG
With over 63,000 employees at more than 1000 locations in over 100 countries, the Kuehne + Nagel Group is one of the world's leading logistics companies. Its strong market position lies in the seafreight, airfreight, contract logistics and overland businesses, with a clear focus on providing IT-based lead logistics solutions.
Further information can be found at www.kuehne-nagel.com
Diese Pressemitteilungen könnten Sie auch interessieren
Vaskuläre Intervention: BIOSOLVE-II belegt Sicherheit und klinische Leistungsfähigkeit des ersten klinisch bewährten bioresorbierbaren Magnesium- Scaffolds
BIOTRONIK, ein führender Hersteller kardio- und endovaskulärer Medizintechnik, hat auf dem diesjährigen TCT Kongress die Ergebnisse der BIOSOLVE-II-Studie...
Vascular Intervention: BIOSOLVE-II Trial Establishes Safety and Clinical Performance of World's First Clinically Proven Magnesium Bioresorbable Scaffold
BIOTRONIK, a leading manufacturer of cardio- and endovascular medical technology, has announced results from the BIOSOLVE-II trial investigating...